GENSCRIPT BIO Reports Q2 Net Trade Sales of CARVYKTI® at Approximately $657 Million

Stock News07-15 20:28

According to an announcement from GENSCRIPT BIO (ASX: 01548), the net trade sales for CARVYKTI® in the quarter ended June 30, 2026, amounted to approximately $657 million.

This figure is reported under the terms of the collaboration and license agreement established between Legend and Janssen Biotech, Inc. on December 21, 2017.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment